Trials show No Advantage for ABMT In Breast Cancer; Should Insurers Pay?
In Brief; “Sense of Urgency” In Research Is Theme of New AACR President Daniel Von Hoff
Clinical Trials: ECOG Says Results In Metastatic disease equivalent, Unlikely To change Over Time
CALGB Says Results In Adjuvant Setting Too Preliminary; Follow Up Planned In Three Years
Komen, ACS Support Payment Off-Protocol; Dilemma for Advocates
NCI Programs: Pediatric Brain Tumor Grants Awarded
Trending Stories
- Maura Gillison, who identified the role of HPV in head and neck cancer, changing the standard of care, dies at 61
- Johnson and Johnson reaches $5.5B settlement deal over talc lawsuits
- What happened at FDA? Replimune approval raises questions
- I grew up unhoused. Now, with support from ACS, I am an MD-PhD student focused on oncology
My mother instilled in me: “Never become a product of your circumstances.” - Duke Officials Silenced Med Student Who Reported Trouble in Anil Potti’s Lab
- FDA grants Replimune’s RP1 an accelerated approval on third submission after 10:3 vote from advisory committee
Amid political outcry, advisors accept weak data and give sponsor a chance to complete phase III trial









